NO951000D0 - Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol - Google Patents

Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol

Info

Publication number
NO951000D0
NO951000D0 NO951000A NO951000A NO951000D0 NO 951000 D0 NO951000 D0 NO 951000D0 NO 951000 A NO951000 A NO 951000A NO 951000 A NO951000 A NO 951000A NO 951000 D0 NO951000 D0 NO 951000D0
Authority
NO
Norway
Prior art keywords
cholesterol
low density
density lipoprotein
total blood
reducing total
Prior art date
Application number
NO951000A
Other languages
English (en)
Norwegian (no)
Other versions
NO951000L (no
Inventor
Steven L Nissen
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO951000(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Publication of NO951000L publication Critical patent/NO951000L/no
Publication of NO951000D0 publication Critical patent/NO951000D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO951000A 1992-09-16 1995-03-15 Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol NO951000D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16
PCT/US1993/008695 WO1994006417A1 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Publications (2)

Publication Number Publication Date
NO951000L NO951000L (no) 1995-03-15
NO951000D0 true NO951000D0 (no) 1995-03-15

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951000A NO951000D0 (no) 1992-09-16 1995-03-15 Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol

Country Status (12)

Country Link
US (1) US5360613A (Direct)
EP (1) EP0660706B1 (Direct)
JP (1) JP3148243B2 (Direct)
AU (1) AU673002B2 (Direct)
BR (1) BR9307035A (Direct)
CA (1) CA2142314C (Direct)
DE (1) DE69327468T2 (Direct)
ES (1) ES2142353T3 (Direct)
FI (1) FI951218A7 (Direct)
NO (1) NO951000D0 (Direct)
NZ (1) NZ256300A (Direct)
WO (1) WO1994006417A1 (Direct)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
AU2620600A (en) * 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
JP4166580B2 (ja) * 2001-05-18 2008-10-15 ロンザ ア−ゲ− ３−ヒドロキシ−３−メチル酪酸ナトリウムの固体組成物の製造方法
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
EP3403516A1 (en) 2008-12-09 2018-11-21 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CA2841748C (en) * 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2744489A4 (en) * 2011-08-15 2015-03-18 Abbott Lab PROCESS FOR THE PREPARATION OF HMB AND SALTS FROM THEREOF
EP2773363A1 (en) 2011-11-03 2014-09-10 University of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
PL3733171T3 (pl) 2012-09-10 2024-03-18 Metabolic Technologies, LLC Kompozycje zawierające hmb i atp oraz ich zastosowanie
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
ES2973467T3 (es) 2015-09-16 2024-06-20 Metabolic Tech Llc Composiciones y métodos de uso de beta-hidroxi-beta-metilbutirato (HMB) para mejorar la recuperación de trauma de tejidos blandos
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
ES2899261T3 (es) * 2015-11-19 2022-03-10 Kyowa Hakko Bio Co Ltd Cristales de una sal de un catión monovalente de ácido 3-hidroxiisovalérico y método para producir dichos cristales
BR112018014920A2 (pt) 2016-01-21 2018-12-18 Metabolic Tech Inc métodos de autofagia por modulação, de tratamento ou redução da probabilidade do início de uma condição mediada por autofagia, de tratamento, inibição, redução, diminuição, ou prevenção de um distúrbio relacionado à idade, de modulação da expressão ou atividade de pelo menos um fator de transcrição, de tratamento, prevenção, diminuição, inibição ou redução de uma condição patológica atribuível a um estado de excesso de nutriente, de promoção de longevidade por autofagia por modulação, de aumento da duração de tempo que um mamífero pode levar um estilo de vida ativo sem sofrer de condições associadas com envelhecimento e de prolongamento do período de saúde de um mamífero.
SG11201811493UA (en) 2016-06-24 2019-01-30 Otsuka Pharma Factory Inc Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
CA3041520A1 (en) 2016-10-21 2018-04-26 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and probiotics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
FI951218A0 (fi) 1995-03-15
JPH08501777A (ja) 1996-02-27
AU4922593A (en) 1994-04-12
EP0660706B1 (en) 1999-12-29
ES2142353T3 (es) 2000-04-16
FI951218L (fi) 1995-03-15
DE69327468T2 (de) 2000-05-11
FI951218A7 (fi) 1995-03-15
NZ256300A (en) 1997-06-24
NO951000L (no) 1995-03-15
AU673002B2 (en) 1996-10-24
WO1994006417A1 (en) 1994-03-31
CA2142314A1 (en) 1994-03-31
US5360613A (en) 1994-11-01
CA2142314C (en) 1999-06-01
EP0660706A1 (en) 1995-07-05
BR9307035A (pt) 1999-06-29
JP3148243B2 (ja) 2001-03-19
DE69327468D1 (de) 2000-02-03
EP0660706A4 (Direct) 1995-07-26

Similar Documents

Publication Publication Date Title
NO951000D0 (no) Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol
NO950774D0 (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
US5271338B1 (en) Tabletop apparatus and method of construction
NO970532D0 (no) System og metode for blodbehandling
KR960703646A (ko) 게임 장치 및 게임의 리플레이 방법(Game Apparatus and Method of Replaying Game)
NO975684D0 (no) Blodbehandlingsutstyr og fremgangsmåte for samling av monokjerneceller
NO933743L (no) Fremgangsmåte og system for gjennomföring av endoskop-kirurgi
NO20001267L (no) Ekspanderbart kateter for veneombinding og fremgangsmÕte for bruk
PL299105A1 (en) Hygenic suspensory and method of making same
DK0594612T3 (da) Præparat til sænkning af cholesterolindholdet i serum og fremgangsmåde til fremstilling af præparater
NO981108L (no) Freseapparat og fremgangsmÕte ved fresing
AU4995693A (en) Apparatus and method for the treatment of blood
KR950702360A (ko) 주파수 선택 방법 및 장치(Frequency Selection Method and Apparatus)
FI942123L (fi) Monivaihelateksin käyttö ja menetelmä monivaihelateksin valmistamiseksi
FI942763A7 (fi) Menetelmä ja laite pienitiheyksisen lipoproteiinin suoran määrityksen tekemiseksi
DK0621974T3 (da) Kirurgisk og/eller klinisk apparat
FI935936L (fi) Menetelmä ja laitteisto sähkökemiallisten laitteiden jäähtymisen estämiseksi
ZA943074B (en) Electrode-carrying catheter and method of making same
NO933417L (no) Luftkondisjoneringsanordning og fremgangsmåte ved luftkondisjonering
UA10998C2 (uk) Спосіб поліфакторhої лікувальhої дії та ковдра для поліфакторhої лікувальhої дії
NO306932B1 (no) Oljeaktig preparat og fremgangsmåte for fremstilling av dette
NO177731C (no) F¶rprodukt og fremgangsmÕte for fremstilling av samme
NO942209D0 (no) Fremgangsmåte og apparat for ekspansjon av tobakk
ZA943203B (en) Method of lowering blood lipid levels
NO963366D0 (no) Peptider og fremgangsmåte for behandling av diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application